Näytä suppeat kuvailutiedot

Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes

Per-Henrik Groop; behalf of the FinnDiane Study Group; Carol Forsblom; Jenny M. Wadén; Emma H. Dahlström; Nina Elonen; Lena M. Thorn; Johan Wadén; Niina Sandholm

dc.contributor.authorPer-Henrik Groop; behalf of the FinnDiane Study Group
dc.contributor.authorCarol Forsblom
dc.contributor.authorJenny M. Wadén
dc.contributor.authorEmma H. Dahlström
dc.contributor.authorNina Elonen
dc.contributor.authorLena M. Thorn
dc.contributor.authorJohan Wadén
dc.contributor.authorNiina Sandholm
dc.date.accessioned2022-10-27T12:17:38Z
dc.date.available2022-10-27T12:17:38Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/157610
dc.description.abstract<h3>Aims/hypothesis</h3><p>Activation of the receptor for AGE (RAGE) has been shown to be associated with diabetic nephropathy. The soluble isoform of RAGE (sRAGE) is considered to function as a decoy receptor for RAGE ligands and thereby protects against diabetic complications. A possible association between sRAGE and diabetic nephropathy is still, however, controversial and a more comprehensive analysis of sRAGE with respect to diabetic nephropathy in type 1 diabetes is therefore warranted.</p><h3>Methods</h3><p>sRAGE was measured in baseline serum samples from 3647 participants with type 1 diabetes from the nationwide multicentre Finnish Diabetic Nephropathy (FinnDiane) Study. Associations between sRAGE and diabetic nephropathy, as well as sRAGE and diabetic nephropathy progression, were evaluated by regression, competing risks and receiver operating characteristic curve analyses. The non-synonymous SNP rs2070600 (G82S) was used to test causality in the Mendelian randomisation analysis.</p><h3>Results</h3><p>Baseline sRAGE concentrations were highest in participants with diabetic nephropathy, compared with participants with a normal AER or those with microalbuminuria. Baseline sRAGE was associated with progression from macroalbuminuria to end-stage renal disease (ESRD) in the competing risks analyses, but this association disappeared when eGFR was entered into the model. The SNP rs2070600 was strongly associated with sRAGE concentrations and with progression from macroalbuminuria to ESRD. However, Mendelian randomisation analysis did not support a causal role for sRAGE in progression to ESRD.</p><h3>Conclusions/interpretation</h3><p>sRAGE is associated with progression from macroalbuminuria to ESRD, but does not add predictive value on top of conventional risk factors. Although sRAGE is a biomarker of diabetic nephropathy, in light of the Mendelian randomisation analysis it does not seem to be causally related to progression from macroalbuminuria to ESRD.</p>
dc.language.isoen
dc.titleSoluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes
dc.identifier.urnURN:NBN:fi-fe2021042823014
dc.relation.volume62
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, vsshp|
dc.contributor.organization-code2607318
dc.converis.publication-id45487080
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/45487080
dc.format.pagerange1268
dc.format.pagerange1274
dc.identifier.eissn1432-0428
dc.identifier.jour-issn0012-186X
dc.okm.affiliatedauthorMetsärinne, Kaj
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.relation.doi10.1007/s00125-019-4883-4
dc.relation.ispartofjournalDiabetologia
dc.relation.issue7
dc.year.issued2019


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot